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ABSTRACT
Mutations in the tumor suppressor gene TP53 contribute to the development 
of approximately half of all human cancers. One mechanism by which mutant p53 
(mtp53) acts is through interaction with other transcription factors, which can either 
enhance or repress the transcription of their target genes. Mtp53 preferentially 
interacts with the erythroblastosis virus E26 oncogene homologue 2 (ETS2), an ETS 
transcription factor, and increases its protein stability. To study the mechanism 
underlying ETS2 degradation, we knocked down ubiquitin ligases known to interact 
with ETS2. We observed that knockdown of the constitutive photomorphogenesis 
protein 1 (COP1) and its binding partner De-etiolated 1 (DET1) significantly increased 
ETS2 stability, and conversely, their ectopic expression led to increased ETS2 
ubiquitination and degradation. Surprisingly, we observed that DET1 binds to ETS2 
independently of COP1, and we demonstrated that mutation of multiple sites required 
for ETS2 degradation abrogated the interaction between DET1 and ETS2. Furthermore, 
we demonstrate that mtp53 prevents the COP1/DET1 complex from ubiquitinating 
ETS2 and thereby marking it for destruction. Mechanistically, we show that mtp53 
destabilizes DET1 and also disrupts the DET1/ETS2 complex thereby preventing 
ETS2 degradation. Our study reveals a hitherto unknown function in which DET1 
mediates the interaction with the substrates of its cognate ubiquitin ligase complex 
and provides an explanation for the ability of mtp53 to protect ETS2.
INTRODUCTION
The majority of human cancers exhibit a loss of 
p53 function either as a result of mutations in the p53 
gene (TP53) or due to dysfunctions in pathways that 
signal to p53 [1]. Mutated forms of p53 (mtp53) proteins 
not only exhibit a loss in wild-type functions, but also 
have dominant negative effect on the wild-type protein, 
rendering it inactive. Studies of p53′s coding sequence 
have shown that more than 80% of its mutations occur 
in its DNA binding domain (DBD) [2]. The majority of 
TP53 mutations can be categorized into DNA contact 
and conformational mutations. DNA contact mutations 
are directly involved in DNA binding (e.g., R248W and 
R273H), and conformational mutations can cause local 
(e.g. R249S and G245S) or global (e.g., R175H and 
R282W) conformational distortions [3]. These changes 
provide multiple functions for mtp53 that can affect 
the genes that are transcribed by wild-type p53 and its 
interaction with other proteins (e.g. transcription factors). 
ChIP-on-chip and ChIP-seq analyses have shown that 
the predominant binding motif in mtp53 target genes 
is GGAAG, which also corresponds to the consensus-
binding site for the erythroblastosis E26 transformation-
specific (ETS) family of transcription factors [4]. The 
ETS family of transcription factors is found throughout 
the metazoan phyla, 28 genes of which are found in 
humans [5]. ETS proteins are sub-classified by the 
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presence of different domains, which can be involved 
in protein-protein interactions (e.g. PNT domain) 
or transcriptional regulation (e.g., ETS domain) [6]. 
Previous studies have shown that mtp53 interacts with 
the ETS subfamily members, ETS erythroblastosis 
virus E26 oncogene homologue (ETS1) and ETS 
erythroblastosis virus E26 oncogene homologue 
2 (ETS2) [4]. Mtp53 has been shown to preferentially 
bind to ETS2 and also to prevent its ubiquitin-dependent 
degradation. ETS2, an evolutionary conserved proto-
oncogene and a downstream effector of the Ras/Raf/
MAPK pathway, regulates the number of genes with 
potentially important functions in cancers such as: tumor 
environment, which includes growth factors, adhesion 
molecules, extracellular proteases and anti-apoptotic 
genes [7].
In this paper we wanted to characterize the 
mechanism by which mtp53 is stabilizing ETS2. 
We hypothesized that mtp53 stabilizes ETS2 by 
preventing its proteasomal degradation. By conducting 
a siRNA screening of most probable candidate ubiquitin 
ligases targeting ETS2, we identified the constitutive 
photomorphogenesis protein 1 (COP1) and the adaptor 
protein De-etiolated 1 (DET11) as negative regulators 
of ETS2 protein stability. COP1 is an E3 ubiquitin ligase 
which can directly or indirectly ubiquitinate its substrates 
with the aid of its RING finger domain. Most studies 
have shown that COP1’s preferred mechanism of action 
consists of promoting substrate degradation through 
other E3 ligases [8]. It was shown that COP1 promoted 
the ubiquitination of transcription factors such as c-Jun 
and the ETS proteins ETS variant 1 (ETV1), ETS variant 
4 (ETV4) and ETS variant 5 (ETV5) by recruiting them 
to the Damage-Specific DNA Binding Protein 1 (DDB1)–
Cullin 4a (Cul4a) E3 ligase complex, an interaction 
mediated by the adaptor protein DET11 [8–10]. We 
determined that ETS2 is a substrate of the COP1/DET11 
ubiquitin ligase complex.
There have been studies showing the regulation 
of ETS2 by ubiquitin ligases [11–13], but none 
describing the mechanism of its protection and 
stabilization by other proteins. Our data indicate that 
mtp53 reduces ubiquitination of ETS2 and protects it 
from proteasomal degradation by COP1/DET11. This 
leads to an accumulation of ETS2, which can cause an 
imbalance in ETS proteins that can lead to deregulation 
of important target genes involved in cancer progression. 
Understanding the dynamics between these two proteins 
will allow us to address possible target genes that may 
play important roles in the transition of normal cells to 
tumor cells. The possibility of disrupting this interaction 
or inhibiting the synergistic relationship between mtp53 
and ETS2 may function as a new approach for possible 
therapeutic targets.
RESULTS
Ubiqutin ligase screening to identify regulator of 
ETS2 stability
Previous studies have reported that ETS2 is 
a substrate of the APC/C and SCF ubiquitin ligase 
complexes. Mouse embryonic fibroblasts lacking Cdhl, 
the adaptor protein of the anaphase promoting complex 
(APC) E3 ubiquitin ligase, exhibit increased ETS2 protein 
stability [11]. Genetic and pharmacological analyses have 
also implicated Cul4a as a regulator of ETS2 stability. 
Additionally, Cul4a has been reported to interact with 
the adaptor protein of the SCF ubiquitin ligase complex, 
Skpla [12, 14]. Other studies have shown that the E3 
ubiquitin ligase COP1 can bind to ETS family members 
and in the presence of its binding partner, DET1, promote 
their degradation [10, 15]. As an initial approach to 
understanding the control of ETS2 turnover, we examined 
the effect of knocking down selected ubiquitin ligases on 
ETS2 protein levels in A549 cells. Western blot analysis 
revealed that knockdown of either COP1 or its binding 
partner DET1 increased ETS2 protein levels (Figure lA, 
lanes: 3, 5). We confirmed the knockdown of DET1 by 
real-time RT-PCR because we were unable to detect it 
using commercially available antibodies (Figure lA, right).
Proteasomal degradration of ETS2 by COP1/
DET1
Next, we wanted to determine if the induction of 
ETS2 after siRNA knockdown of COP1 and DET1 was 
a result of increased ETS2 protein stability. We knocked 
down COP1 and DET1, and assessed the rate of ETS2 
protein turnover. Transfected cells were treated with 
cycloheximide (CHX) and harvested at different time 
points for Western blot analysis (Figure lB). In order to 
have the same amount of ETS2 at the first time point 
(0 or unt) measured under all conditions, we initially 
treated the cells with MG-132 to prevent its degradation 
and then added fresh media containing CHX. In control 
siRNA transfected cells, ETS2 protein levels almost 
completely disappeared after 1 hour of CHX treatment 
(Figure 1B, top left panel: lane 3, bottom left panel). With 
COP1 knockdown, ETS2 protein levels were higher at time 
points 0, 0.5, 1, and 2 hours (Figure 1B, top left panel: 
lanes 6–9, bottom left panel). The highest levels of ETS2 
protein were observed in the DET1 knockdown samples. 
The knockdown of DET1 was verified by  RT-PCR as 
above (Figure 1B, top right panel). These levels were 
approximately two times higher in time points 0, 0.5, and 
1 hour than those seen in the control and COP1 
knockdowns (Figure 1B, top left panel: lanes 11–13, 
bottom left panel). This suggests that ETS2 protein stability 
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is controlled by an ubiquitin ligase complex containing 
COP1 and DET1. We did note that ETS2 was still degraded 
in the absence of COP1 and DET1, suggesting that there 
are other ubiquitin ligases that promote its degradation.
To confirm that COP1 and DET1 promote ETS2 
degradation, we performed a degradation assay in which 
we co-transfected increasing amounts of Myc-COP1 COP1 
and Myc-DET1DET1 with a fixed amount of Myc-ETS2 
and assessed ETS2 levels by Western blot. We observed 
that co-transfection of COP1 and DET1 led to a decrease 
in ETS2 protein in a dose dependent manner (Figure lC, 
lanes 2–5). Previously it has been reported that COP1 
requires an intact RING domain to degrade its substrates 
including other ETS proteins [10, 16–18]. To address 
whether or not this was the case for ETS2, we generated a 
RING domain mutant [9, 10] and used it in the degradation 
assay. As with other ETS family members, ETS2 was not 
degraded by the COP1 RING mutant, confirming that a 
structurally intact RING domain is crucial for COP1 to 
promote ETS2 degradation (Figure lC).
To establish that ETS2 is a direct substrate of 
COP1, we assessed if there was an interaction between 
the endogenous proteins. To capture the ETS2/COP1 
complex, A549 cells were treated with MG-132 to prevent 
ETS2 destruction and then cell lysates were subjected to 
immunoprecipitation with an anti-ETS2 antibody. Western 
blot analysis showed that COP1 co-immunoprecipitated 
with ETS2 (Figure 1D, left).
Figure 1: siRNA screening indicates COP1/DET1 are involved in ETS2 protein stability. (A) ETS2 stability in the absence of 
candidate ubiquitin ligases. A549 (WTp53) cells were transfected with siRNAs targeting Cdhl, COP1, Cul4a, DET1 and Skpla for 48 h. Cells 
were lysed and processed for Western blotting. (A, right) Relative quantity expression of DET1 mRNA after DET1 siRNA knockdown for 
48 h. (B) Cycloheximide (CHX) chase experiments for ETS2. (B, left) A549 cells were treated with control, COP1 and DET1 siRNA, for 48 
h. Before harvesting, the cells were treated with MG-132 for l.5 h. After MG-132 treatment, the media was removed and replaced with fresh 
media containing l0 μg/mL of CHX. The samples were harvested at 0, 0.5, l, 2, 3 h followed by Western blotting. (B, bottom) Densitometry 
analysis with ImageJ for relative ETS2 protein levels normalized to the 0 h timepoint for each knockdown. (B, right) Relative quantity 
expression of DET1 mRNA after DET1 siRNA knockdown for 48 h. (C) Degradation of ETS2 by COP1/DET1. A549 cells were transfected 
with either wild-type COP1 or COP1 with the mutated RING residues Cl36A and Cl39A, DET1, and ETS2 for 24 h. Lysates were then 
harvested and processed for Western blotting. Solid triangle indicates increasing amounts of plasmid. (D) Co-immunoprecipitation of 
ETS2 with COP1 and DET1. (D, left) A549 cells were treated with MG-132 for 6 h followed by immunoprecipitation with anti-ETS2 (E-5) 
antibody. Immunoprecipitates were processed for Western blotting with anti-COP1 and anti-ETS2 antibody. (D, right) Lysates of PC3 (p53 
null) cells transiently expressing COP1, DET1 and ETS2 for 24 h were immunoprecipitated with anti-ETS2 (C-20) antibodies. Prior to 
harvesting, the cells were treated with MG-132 for 6 h. Immunoprecipitates were processed for Western blotting with anti-Myc antibodies.
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COP1 and DET1 are found in a multisubunit ubiquitin 
ligase complex containing DDBl, Cul4a, and a putative 
undefined factor (referred to as X-box). In this context, 
DET1 is thought to associate with the DDBl/Cul4a ubiquitin 
ligase complex by interacting with the β-propellers in the 
DDBl protein’s structure through a DET1 α-helical motif, 
H-Box [19]. The substrate specificity of this complex is 
imparted by the association of COP1 with specific binding 
motifs in the substrates. Hence, DET1 serves to assemble 
the multi-subunit ubiquitin ligase complex and COP1 
functions as an adaptor subunit that recruits substrates for 
ubiquitination and subsequent degradation [9, 15].
Our siRNA data showed that DET1 knockdown also 
induced ETS2. Thus, we wanted to confirm that COP1, 
DET1 and ETS2 formed a complex. We performed co- 
immunoprecipitation experiments in PC3 cells, which lack 
COP1 [10, 20]. We transfected Myc-tagged versions of 
ETS2, COP1 and DET1 and then immunoprecipitated ETS2 
to detect associated proteins. In agreement with the model in 
which COP1 binds to substrates, we detected an interaction 
between ETS2 and COP1 (Figure 1D, right: lane 3). 
Surprisingly, even though DET1’s recognized function is 
to assemble the multi-subunit ubiquitin ligase complex, we 
detected an interaction between ETS2 and DET1 (Figure lD, 
right: lane 4). Since these cells lack COP1, this data suggests 
that DET1 directly interacts with ETS2. Given that previous 
studies have reported that DET1 does not interact with 
substrates of this ubiquitin ligase complex, our data reveal a 
non-canonical activity of DET1 [9, 15].
Domains in ETS2 required for COP1/DET1 
degradation
COP1 recognizes a degron motif that permits the 
interaction and subsequent degradation of its substrates. 
The amino acid sequence of ETS2 lacks a canonical 
COP1 degron motif; thus we took an unbiased approach to 
identify the residues required for its degradation. We tested 
the ability of COP1/DET1 to degrade Myc-tagged ETS2 
deletion mutants that lack different portions of the protein 
(Δ8–l04, Δl05–204, Δ205–304, Δ305–404, Δ405–465). 
We found that the deletion mutant Δ8–l04 was protected 
Figure 2: ETS2 amino acids V52, P53 and V308, P309 correspond to COP1 binding motifs required for degradation 
and interaction. Degradation of ETS2 deletion and VP mutants by COP1/DET1. (A) A549 cells were transfected with either full-length 
ETS2 or with the mentioned ETS2 deletion constructs, COP1 and DET1, for 24 h. (B, C) A549 cells were transfected with either wild-
type ETS2 or with the mentioned ETS2 VP constructs, COP1 and DET1 for 24 h. Lysates were then harvested and processed for Western 
blotting. (D) Lysates of PC3 cells transiently expressing COP1, DET1 and the mentioned ETS2 VP mutants were immunoprecipitated with 
anti-ETS2 (C-20) antibodies. The immunoprecipitates were processed for Western blotting with anti-Myc antibodies.
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from COP1/DET1 degradation (Figure 2A, lanes 4, 5). 
Similarly, the Δ305–404 deletion mutant, despite having 
lower expression levels, was relatively refractory to COP1/
DET1 degradation (Figure 2A, lanes 10, 11). These data 
indicate that a sequence within this region is required for 
ETS2 degradation by the COP1/DET1 complex.
The degron motif V-P-E/D-X-G (X corresponds to 
a hydrophobic residue) is required for the recognition of 
substrates by COP1 [21]. As the Δ8–l04 and Δ305–404 
deletion mutants were not degraded by COP1/DET1, we 
searched within the deleted regions for he conserved VP 
residues. We identified two putative partial COP1 degron 
motifs, one at amino acids 52 and 53 (V52,P53) and another 
in amino acids 308 and 309 (V308,P309). As this did not 
constitute a complete COP1 degron motif, we opted to 
search the rest of the ETS2 sequence for a similar motif to 
use as a control, identifying residues in amino acids l87 and 
l88 (Vl87,Pl88).
We mutated these putative COP1 degron sites to 
alanines (V52A,P53A, Vl87A,Pl88A, and V308A,P309A) 
and tested them in the degradation assay. The V52A,P53A 
mutant was not degraded by COP1/DET1 (Figure 2B, 
lanes 6–9). The V308A,P309A was partially resistant to 
degradation (Figure 2C, lanes 10–13) but the Vl87A,Pl88A 
was not (Figure 2C, lanes 6–9). These data agree with our 
results above and indicate that a degron motif is harbored 
within amino acids 8–l04 and 305–404 of ETS2.
To test if the ETS2 VP mutants were protected 
from degradation because they were not recognized by 
COP1, we assessed their ability to interact with COP1 and 
DET1 in the PC3 cells. The interaction between the ETS2 
V52A,P53A mutant and COP1 was severely compromised 
(Figure 2C, lane 7) but the V308A,P309A mutant bound as 
well as wild-type ETS2 (Figure 2C, lanes: 3,11). Strikingly, 
mutation of either of these VP sites virtually eliminated the 
interaction with DET1 (Figure 2D, lanes: 8, 12). The fact 
that the mutation of these sites protects ETS2 from COP1/
DET1 mediated degradation suggests that the interaction 
with DET1 is required for ETS2 destruction. Therefore, 
DET1 plays a non-canonical role in the degradation of 
ETS2 in that it not only serves by forming a bridge between 
the ubiquitin ligase complex and COP1, but also by serving 
as a substrate-binding adaptor.
COP1 participates in CDK10 destruction of 
ETS2
Previous studies have reported that the cyclin dependent 
kinase l0 (CDK10) negatively regulates ETS2’s transactivation 
activity and that it can phosphorylate ETS2 and promote its 
ubiquitin-dependent degradation [13, 22–24]. However, the 
ubiquitin ligase that cooperates with CDK10 to degrade ETS2 
is not known. We confirmed that co-expression of CDK10 and 
ETS2 leads to degradation of the latter (Figure 3C, lanes: 4–6). 
Figure 3: COP1/DET1 aid in the CDK10 mediated degradation of ETS2. Degradation of ETS2 wild-type and alanine mutants 
by COP1/DET1 and CDK10. (A) PC3 cells were transfected with wild-type ETS2, CDK10, and a set amount of CDK10 with increasing 
amounts of COP1 for 24 h. (B) PC3 cells were transfected withwild-type ETS2, CDK10, and a set amount of COP1 with increasing amounts 
of CDK10. (C) A549 cells were transfected with either wild-type ETS2 or with the mentioned ETS2 alanine mutants and CDK10 for 24 h. 
(D) A549 cells were transfected with either wild-type ETS2 or with the mentioned ETS2 alanine mutants, COP1 and DET1, for 24 h. (A, B, C, D) 
Lysates were then  harvested and processed for Western blotting. Solid triangle indicates increasing amounts of plasmid.
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In contrast to what was observed in COP1 expressing cells, 
increasing amounts of CDK10 in COP1 null PC3 cells yielded 
only a modest decrease in ETS2; moreover, that decrease 
plateaued and failed to completely eliminate ETS2 (Figure 3A, 
lanes: 4–6). To determine if CDK10 requires COP1/DET1 to 
promote ETS2 degradation, we determined if co-transfection 
of COP1 facilitated CDK10 degradation of ETS2. We found 
that co-transfection of COP1 with CDK10 and ETS2 resulted 
in complete elimination of ETS2, suggesting that COP1 is 
required for CDK10 to fully promote ETS2 degradation 
(Figure 3A, 3B, lanes: 7–9).
Having established that COP1 mediates the 
destruction of ETS2, we wanted to determine any existing 
interplay between the CDK10 phosphorylation sites in ETS2 
and the ability of COP1/DET1 to mediate its degradation. 
CDK10 has been shown to phosphorylate multiple sites 
in ETS2, but most notably, serines 220 and 225 appear to 
be important to ETS2 degradation [13]. Co-transfection of 
CDK10 with an ETS2 mutant in which we changed these 
serines to alanines (S220A,S225A) revealed that mutation 
of these amino acids provides some protection from 
degradation (Figure 3C, lanes: 7–9). Likewise, mutation 
of serine 220 and 225, either alone or combined, provided 
protection of ETS2 from COP1 degradation (Figure 3D, 
lanes: 5, 7, 9). As CDK10 reportedly phosphorylates other 
sites (serines 246, 248, 255 and 3l9) in ETS2 [ 1 3 ] , we 
tested whether or not they regulated ETS2 destruction.
Individual mutation of these amino acids failed to 
consistently yield protection from CDK10 degradation 
(data not shown). Our observation that mutation of serine 
220 or 225 alone provided a small degree of protection for 
ETS2 led us to speculate that phosphorylation of a certain 
combination of these residues cooperatively regulates ETS2 
stability. Therefore, we mutated different combinations and 
again assessed whether or not they were protected from 
degradation (Figure 4A–4D). Of the different combinations, 
we noted that mutation of serines 220, 225 and 248 provided 
the highest protection in the degradation assay (Figure 4A, 
lanes: 6, 7) compared to mutation combinations of serines 
220, 225, 246, 248 (Figure 4B, lanes: 6, 7) and 220, 225, 
246, 248, 255 (Figure 4C, lanes: 6, 7). The mutant affording 
the second highest level of protection from degradation was 
the ETS2 phosphorylation mutant, in which all the putative 
CDK10 phosphorylation sites described were mutated to 
alanines (Figure 4D, lanes: 6, 7). Since mutation of these 
sites conferred protection from degradation, our data suggest 
their phosphorylation by CDK10 (S220, S225, S248) likely 
marks ETS2 for COP1/DET1 mediated degradation.
We demonstrated above that DET1 interacts with 
ETS2 independently of COP1 and that mutation of the 
Figure 4: ETS2 alanine mutants for CDK10 phosphorylation sites are less susceptible to CDK10 mediated degradation. 
(A, B, C, D) CDK10  mediated degradation of ETS2 alaninemutants.A549 cells were transfected with either wild-type ETS2 or 
withthementioned ETS2 alanine mutants and CDK10 for 24 h. Lysates were then harvested and processed for Western blotting. Solid triangle 
indicates increasing amounts ofplasmid.
Oncotarget12560www.impactjournals.com/oncotarget
Figure 5: Alanine mutations of CDK10 serine phosphorylation sites in ETS2 disrupt DET1 binding and reduces COP1 
interaction. Co-immunoprecipitation of ETS2 wild-type or the mentioned alanine mutants with DET1 (A) and COP1 (B). PC3 cells were 
transfected with either wild-type ETS2 or the mentioned alanine mutants and DET1 (A) or COP1 (B) for 24 h. Samples were treated with 
MG-132 for 6 h prior to harvesting. Lysates were then immunoprecipitated with anti-ETS2 (C-20) antibodies (A) or anti-COP1 antibodies (B) 
and then processed for Western blotting.
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minimal consensus sequence of COP1 degrons eliminates 
the ETS2/DET1 interaction and prevents ETS2 degradation. 
These data suggest that the interaction between ETS2 and 
DET1 is critical for ETS2 degradation; thus we next sought 
to determine if ETS2 could be protected from degradation 
by preventing the interaction between serine triple mutant 
(S220, S225, S248) and DET1. To test this possibility, 
we compared the interaction between several ETS2 
phosphorylation mutants and DET1. Mutation of serines 
220 and 225 resulted in a pronounced decrease in the ETS2 
and DET1 interaction (Figure 5A, lane 4). Moreover, 
mutation of serines 220, 225 and 248 further reduced this 
interaction (Figure 5A, lane 5). Mutation of additional 
residues (serines 246, 255 and 3l9) did not prevent the 
association of ETS2 with DET1 (Figure 5A, lane 6). We 
proceeded to also assess the interaction between the ETS2 
phosphomutants and COP1. COP1 was not affected by 
ETS2 mutations in serines 220 and 225 (Figure 5B, lane 5). 
Figure 6: Mtp53 decreases ubiquitination and protects ETS2, and not other ETS proteins, from COP1 and DET1 
degradation. Degradation and ubiquitination assay of ETS2. (A) A549 cells were co-transfected with ETS2, COP1 and DET1 with 
or without mtp53 R248W. Cells were harvested after 24 h, followed by Western blotting. Solid triangle indicates increasing amounts 
of plasmid. (B) A549 cells were co-transfected with ETVl, ETV4, or ETV5, and each with COP1 and DET1, with and without mtp53 
R248W. Cells were harvested after 24 h, followed by Western blotting. (C) A549 cells were transfected for 24 h with ETS2, poly ubiquitin, 
COP1, DET1, and mtp53 R248W. Prior to harvesting, cells were treated with MG-132 for 6 h. Cells were harvested under denaturing 
conditions by using boiling l% SDS buffer, which was then diluted to RIPA buffer. Lysates were then immunoprecipitated with anti-ETS2 
(C-20) antibodies. Immunoprecipitates were processed for Western blotting with anti-HA antibodies. (D) Mtp53 protects ETS2 for CDK10 
mediated degradation. CDK10 mediated degradation assay of ETS2. A549 cells were co-transfected with ETS2 and CDK10 with or without 
mtp53 R248W. Cells were harvested after 24 h, followed by Western blotting.
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However, mutants (serines 220, 225, 248) (Figure 5B, lane 6) 
and (serines 220, 225, 246, 248, 255, 3l9) (Figure 5B, lane 7) 
showed a decrease in interaction. Our data therefore suggest 
that phosphorylation of serines 220, 225 and 248 in part 
serves as the signal codifying ETS2 for destruction.
Mutant p53 protects ETS2 from COP1/DET1 
degradation
Previously we reported that mtp53 interacts with 
ETS2 and protects it from uibiquitin-mediated degradation 
[4]. Importantly, WTp53 interacts poorly with ETS2 and 
it does not prevent degradation of the latter [4]. Using a 
series of deletion mutants, we showed that mtp53 binds 
to ETS2 in a region encompassing amino acids 225–264. 
Given the overlap between the mtp53 binding region and 
the CDK10 phosphorylation sites in ETS2, we speculated 
that mtp53 stabilizes ETS2 by masking these sites from 
being recognized by DET1. By assuming this to be so, we 
further predicted that mtp53 should protect ETS2 from 
COP1/DET1 mediated degradation. Co-transfection of 
ETS2 with increasing amounts of COP1/DET1 led to ETS2 
destruction, but importantly, when we included mtp53 in 
the degradation assay we observed that mtp53 potently 
prevented ETS2 degradation (Figure 6A, lanes: 7–9 and 
Supplementary Figure 1, lanes: 7–9).
Although we speculated that mtp53 protects ETS2 
by masking the region bound by the COP1/DET1 complex, 
an alternative mechanism by which mtp53 protects ETS2 
could be by inactivating COP1 ubiquitin ligase activity. To 
address this possibility, we performed degradation assays 
with the other ETS family members (ETVl, ETV4, and 
ETV5), which are known substrates of this ubiquitin ligase 
complex: mtp53 failed to protect these other ETS family 
members, suggesting that it only protects ETS2 (Figure 6B). 
The continued degrading of ETVl, ETV4 and ETV5 by 
COP1/DET1 indicates that mtp53 does not inhibit the 
ubiquitin ligase activity of this complex.
To further substantiate that mtp53 prevents the 
ubiquitin-mediated destruction of ETS2, we performed 
an ubiquitination assay by transfecting all components 
used in the degradation assay, including HA-tagged 
ubiquitin, in order to observe the extent of ubiquitination. 
For this experiment, ETS2 was immunoprecipitated under 
denaturing conditions to prevent the co-precipitation 
of other ubiquitinated proteins; this done, we detected 
ubiquitination with an antibody against the HA-tag. 
Transfection of ETS2 with HA-ubiquitin revealed that 
ETS2 is actively ubiquitinated (Figure 6C, lane 3). When 
we also included COP1/DET1 in the transfection, we 
observed markedly increased ubiquitination (Figure 6C, 
lane 4). In agreement with the ability of mtp53 to protect 
ETS2 from degradation, we further observed that the 
inclusion of mtp53 in the transfection largely reduced 
the extent of ubiquitination (Figure 6C, lane 5). Of note, 
co-transfection of mtp53 with ETS2 and HA-ubiquitin 
virtually eliminated the basal ubiquitination level 
(Figure 6C, lane 6). Taken together, our data indicate that 
mtp53 specifically prevents the COP1/DET1 mediated 
ubiquitination and degradation of ETS2.
Consistent with the ability of mtp53 to protect 
ETS2, we observed that mtp53 partially rescued ETS2 
from CDK10 (Figure 6D, lane 4). We noticed that in the 
presence of mtp53, both COP1 and DET1 were expressed 
Figure 7: Mtp53 destabilizes DET1 and blocks the interaction between DET1 and ETS2. (A, B, top) A549 cells were 
transfected with the indicated plasmids and protein turnover was assessed after blocking new protein synthesis with CHX. (A, bottom) 
Densitometry analysis for relative DET1 or COP1 (B, bottom) protein levels normalized to the 0 h timepoint for each tranfection. (C) 
Co-immunoprecipitation of ETS2 with COP1, DET1, with or without mtp53. PC3 cells were transfected with ETS2, COP1, DET1, and mtp53 
R248W for 24 h. Samples were treated with MG-132 for 6 h prior to harvesting. Lysates were then immunoprecipitated with anti-ETS2 (C-20) 
antibodies and then processed for Western blotting. Solid triangle indicates increasing amounts of plasmid.
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at lower levels. To determine whether or not mtp53 affected 
the stability of these proteins, we co-transfected them 
and examined their half-life in the presence of mtp53. 
Densitometry analysis revealed that just after 2 hours, DET1 
had a markedly higher turnover in the presence of mtp53, 
suggesting that the protein was less stable (Figure 7A, 
top lanes: 5–8 and bottom). In a separate experiment, 
Western blot analysis revealed that COP1 protein turnover 
was not affected to the same magnitude as was DET1 
by the presence of mtp53 (Figure 7B, top lanes: 4–6 and 
bottom). The results of these experiments suggested that 
mtp53 protects ETS2 from degradation by destabilizing 
DET1. If so, we would expect to find less DET1 bound to 
ETS2 in the presence of mtp53.
To directly assess this possibility, we co-transfected 
the COP1 null PC3 cells [20] with different combinations of 
COP1, DET1, ETS2 and mtp53 to assess their interactions. 
As before, we could detect the interaction between COP1/
DET1 and ETS2 by immunoprecipitation. In contrast, the 
inclusion of increasing amounts of mtp53 in this transfection 
reduced the amount of DET1 that co-precipitates with 
ETS2 (Figure 7C, lanes: 5–7). Nevertheless, the interaction 
between ETS2 and COP1 was only minimally affected.
Our early results in the present work suggested that 
an association of DET1 with ETS2 is required for ETS2 
degradation. The role of mtp53 in reducing DET1 levels 
suggests that mtp53 protects ETS2 from degradation by 
controlling the abundance of DET1, a critical component 
of the ubiquitin ligase complex. In addition, the fact that 
mtp53 and DET1 appear to bind to the same region in 
ETS2 suggests that the proteins may compete for binding 
to these sites. Such competition, in tandem with the 
reduction of DET1 levels, would allow mtp53 to protect 
ETS2 from destruction by disrupting the interaction 
between DET1 and ETS2.
We previously demonstrated that ETS2 knockdown 
reduced cell invasion, indicating that ETS2 has a key 
role in regulating this cellular activity [25]. Since COP1 
knockdown induced ETS2, we examined if this also 
increased cell invasion. In both A549 and A375 cells, 
COP1 knockdown induced ETS2 protein levels, which 
correlated with increased invasion (Figure 8A).
In addition to promoting ETS protein degradation, 
COP1 has been reported to inhibit the ETS protein family’s 
transcriptional activity [15]. Since mtp53 protected ETS2 
from COP1/DET1 mediated degradation, we decided 
to test whether or not it could also prevent COP1 from 
interfering with ETS2’s transcriptional activity. As we had 
recently reported that ETS2 transcriptionally activates the 
promoter for deoxcytidine kinase (dCK) [26], we used 
a dCK promoter luciferase construct for this analysis. 
In this experiment, we transfected ETS2 with the dCK 
Figure 8: Opposing control of ETS2 by mtp53 and COP1 affects ETS activity. (A) Hl299 (p53 null) cells were transfected 
with the indicated plasmids and the dCK promoter luciferase construct. The cells were harvested 24 h later and luciferase activity was 
measured. (A, B) Shown is the average of two independent experiments with ± SE. (B) A549 and A375 (WTp53) cells transfected with 
either a control or COP1 siRNA were assessed for their invasive activity. Top panel: representative images of invading cells; middle panel: 
quantitation of invasive cells using a cell counter plug-in for the ImageJ software. Statistical analysis was conducted using an unpaired 
homoscedastic t-test included in the Graph Pad Prism software, *indicates p < 0.05 relative to control knockdown; bottom panel: Western 
blot analysis of siRNA transfected cells.
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promoter luciferase construct and examined the impact of 
co-transfecting COP1. Co-transfection of COP1 resulted 
in an almost 50% decrease in dCK promoter activity. 
Strikingly, transfection of ETS2, COP1 and mtp53 fully 
restored the activity of the promoter construct (Figure 8B). 
Taken together, these data indicate that mtp53 prevents 
COP1 from inhibiting ETS2.
DISCUSSION
We report that COP1 and DET1 are part of an 
ubiquitin ligase that marks ETS2 for degradation. While 
this work was in progress, another study demonstrated 
the same regulation of ETS2 by COP1 [27]. However, 
despite the overlying similarities in our conclusions, 
we observed a distinct mechanism by which ETS2 is 
controlled by this ubiquitin ligase complex. In our study, 
mutation of the first VP degron site reduced COP1 binding 
dramatically, whereas mutation of the second VP site did 
not. We made the surprising observation that DET1 binds 
to ETS2 independently of COP1, and that mutation of 
either VP degron site prevents this association. Moreover, 
we provide the first evidence indicating that DET1 has a 
role beyond its well accepted scaffolding function in the 
formation of this ubiquitin ligase complex.
We further characterized the regulation of ETS2 by 
showing that the COP1/DET1 ubiquitin ligase complex 
is important for the degradation of ETS2 by CDK10. In 
addition, we demonstrated that DET1 cannot bind an ETS2 
mutant in which the CDK10 phosphorylation sites have 
been mutated to alanines. This observation suggests that 
phosphorylation of ETS2 by CDK10 creates a recognition 
motif for DET1. However, COP1/DET1 are still able to 
degrade an ETS2 deletion mutant lacking amino acids 
205–304 (which harbors the CDK10 sites), it is possible 
that this portion of the protein is subject to conformational 
changes that affect ETS2’s ability to interact with COP1/
DET1. In this case, the phosphorylation sites within 
this region may play a role in regulating the interaction 
with COP1/DET1 by impacting its conformation. 
Nevertheless, the fact that mutation of either the VP 
sites or CDK10 phosphorylation sites in ETS2 strongly 
inhibits its interaction with DET1 reinforces the notion 
that DET1 plays a novel function in the recognition of 
this ubiquitin ligase substrate. Importantly, we found that 
mtp53 prevents ETS2 degradation by competing with 
DET1 for binding to the region harboring the CDK10 
phosphorylation sites. We also found that DET1 protein 
turnover was accelerated in the presence of mtp53. Thus, 
mtp53 appears to protect ETS2 by both displacing and 
destabilizing DET1.
Previous studies have proposed a role for COP1 as 
a tumor suppressor gene [9, 10, 20, 28]. We previously 
showed that ETS2 knockdown reduces cell invasion and 
in this study we demonstrated that COP1 knockdown 
resulted in increased ETS2 levels and increased cell 
invasion. Taken together, these data identify the control of 
ETS2 levels as a fundamentally important mechanism for 
suppressing cancer cell phenotypes. The fact that mtp53 
blocks the COP1/DET1 complex from degrading ETS2 
and also prevents COP1 from inhibiting the transcriptional 
activity of ETS2 suggests that mtp53 may exert some of 
its oncogenic functions by disrupting the homeostatic 
regulation of ETS2. To our knowledge, it appears that 
among the different transcription factors that interact 
with mtp53, only ETS2 is protected from degradation. 
Given that approximately half of all the mtp53 binding 
sites in the genome harbor an ETS motif, our data indicate 
that by protecting its preferred binding partner, ETS2, 
mtp53 enhances its ability to transcriptionally regulate 
a multitude of genes involved in cancer progression.
MATERIALS AND METHODS
Cell culture, inhibitors, and siRNAs
All cell lines used in this study were purchased from 
the American Tissue Culture Collection (ATCC, Manassas, 
VA, USA). A375 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented 
with 10% FBS. A549 and PC3 cells were cultured in 
Roswell Park Memorial Institute medium (RPMI-1640) 
supplemented with l0% FBS. Cells were seeded in 12-well 
(0.l25 × 106 cells) and 6-well (0.3 × 106 cells) plastic plates, 
60 mm (l × 106 cells) and l45 mm (10 × 106) dishes (Greiner 
Bio-One, Monroe, NC, USA) and allowed to attach for 24 h 
prior to the experiment. The Cycloheximide (CHX) and 
MG-132 inhibitors used in this study were both purchased 
from Sigma-Aldrich (St. Louis, MO USA). Control, Cdhl, 
Cul4a, and Skpla targeted siRNAs were purchased from 
Qiagen (Valencia, CA, USA). RFWD2/COP1 and DET1 
targeted siRNA were purchased from Integrated DNA 
technologies (IDT) (Coralville, IA, USA).
Plasmid constructs
pCMV-Myc-ETS2 wild-type and deletion mutants, 
HA-mtp53 R248W, Flag-ETVl, Flag-ETV4, Flag-ETV5, 
pCMV-β-galactosidase and HA-poly ubiquitin plasmids 
have been described previously [29]. Human COP1 and 
DET1 cDNA (GE Dharmacon, Lafayette, CO, USA) 
was amplified by PCR and subcloned into pCMV-Myc 
(Clontech, Mountain View, CA, USA). pCMV-Myc 
COP1 was used as a template to generate the COP1 RING 
mutant Cl36ACl39A. pCMV-Myc-ETS2 construct was 
used as a template to generate mutations V52AP53A, 
Vl87APl88A, and V308AP309A. All mutagenesis was 
accomplished using the Q5® Site-Directed Mutagenesis 
Kit from New England BioLabs (Ipswich, MA, USA) 
and appropriate mutagenesis primers generated by using 
the NEBaseChanger™ tool. Mutations were verified by 
sequencing.
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Determination of protein stability
A549 cells were transfected with siRNA targeting 
either Control, Cdhl, COP1, Cul4a, DET1, and Skpla 
using Lipofectamine® RNAiMAX according to the 
manufacturer’s protocol (Life Technologies, Grand 
Island, NY, USA). Cell lysates were harvested in 48 h 
after transfection using RIPA buffer followed by 
sonication and centrifugation. Estimation of protein 
estimation was done with the Pierce BCA Protein Assay 
Kit (Thermo Fisher Scientific, Waltham, MA, USA) 
prior to subjecting the lysates to Western blotting. 
Cycloheximide-pulse chase experiments were conducted 
by replacing the media of A549 cells with media 
containing CHX and harvesting at different time points. 
Samples were then processed for Western blotting. 
A549, H1299, or PC3 cells were co-transfected with and 
pCMV-β-galactosidase by using Lipofectamine®2000 
(Life Technologies, Carlsbad, CA, USA) according 
to the manufacturer’s protocol for 24 h. Samples 
were harvested by adding immunoprecipitation (IP) 
lysis buffer [4] and rocked for l0 min at 4°C. Lysates 
were then collected followed by gentle sonication 
and centrifugation. Samples were normalized to 
β-galactosidase expression prior to Western blotting 
by using the Pierce beta-Galactosidase Assay Reagent 
(Thermo Fisher Scientific, Waltham, MA, USA) 
according to the manufacturer’s protocol.
Immunoprecipitations
Endogenous interaction of ETS2 and COP1 was 
detected by treating A549 cells with 20 μM of MG-132 
for 6 h. Cells were then harvested by using IP lysis buffer 
followed estimation of protein concentration. The sample 
was normalized and split followed by incubation with 1 
μg of either monoclonal IgG or ETS2 (E-5) monoclonal 
antibodies per mg of total protein. The samples were 
rocked overnight at 4°C, after which they were incubated 
with Protein G beads (KPL, Gaithersburg, MD, USA) for 
2 h at 4°C. Protein G beads were then washed with IP 
lysis buffer 5×, followed by adding sample loading buffer 
and boiling for l0 min. Samples were then subjected to 
Western blotting. ETS2 ubiquitination analysis was done 
by transfecting A549 cells for 24 h followed by MG-132 
treatment 6 h prior harvesting. Cells were harvested by 
lysing with l% SDS in PBS boiling buffer. Lysates where 
then boiled at l00°C for l0 min followed by sonication. 
The samples’ buffer was adjusted to a stringent 
buffer described previously [30]. Samples were then 
incubated with 0.5 μg of rabbit ETS2 (C-20) polyclonal 
antibodies and rocked for 2 h at 4°C. Protein G 
beads were added to the lysates for l h followed by 
washing with the stringent buffer 5×. Sample buffer 
was added to the beads followed by boiling for l0 min. 
Samples were then subjected to Western blotting.
Western blotting and antibodies
All Western blotting was conducted as described 
previously [4]. Primary mouse monoclonal antibodies for 
Western blots were anti-p53 (DO-l; sc0l26; Santa Cruz 
Biotechnologies, Dallas, TX, USA), anti-Ets-2 (E-5; sc-
365666; Santa Cruz Biotechnologies, Dallas, TX, USA), 
anti-Myc (9El0; sc-40; Santa Cruz Biotechnologies, 
Dallas, TX, USA), anti-FLAG (M2; F3l65; Sigma-
Aldrich, St. Louis, MO, USA) and anti-HA-probe (F-7; 
sc-7392; Santa Cruz Biotechnologies, Dallas, TX, USA). 
Rabbit polyclonal antibodies used for Western blots were 
anti-Ets-2 (C-20; sc-35l; Santa Cruz Biotechnologies, 
Dallas, TX, USA) and anti-COP1/RFWD2 (A300–
894A; Bethyl, Montgomery, TX, USA). Mouse and 
Rabbit secondary antibodies were from Cell Signaling 
Technology (Danvers, MA, USA).
Luciferase assay
Cell based luciferase assays were performed 
using the dual luciferase Promega (Madison, WI, USA) 
kit. H1299 cells were seeded in a white 96-well clear 
bottom plates. 24 h after transfection, luciferase activity 
was measured according to manufacturer’s instructions. 
Reporter activity from internal control was used to 
normalize the test reporter data. Fold changes were 
calculated by normalizing pGL4-dCK reporter activity 
towards pGL4 empty vector wells.
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